Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Sermorelin

GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate

A synthetic 29-amino acid analog of growth hormone-releasing hormone that stimulates pituitary gland to release growth hormone.

Quick Stats
Studies 223
Trials 41
Formula C149H246N44O42S
Clear All
Utility 4
pubmed 1997

Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women.

Khorram. O O; Yeung. M M; Vu. L L; Yen. S S SS

A 5‑month study gave older adults a nightly injection of a GHRH peptide (similar to sermorelin) at 10 µg per kg. Within weeks their GH and IGF‑1 levels rose and several immune cells (B cells, T‑cell activation markers, NK cells) increased, with no side‑effects reported.

Utility 4
pubmed Dec 1, 1987

GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH.

Ross. R J RJ; Tsagarakis. S S; Grossman. A A; Nhagafoong. L L; Touzel. R J RJ; Rees. L H LH; Besser....

The study shows that boosting the body's cholinergic activity with pyridostigmine can raise natural growth hormone (GH) levels and make the body respond more strongly to GH‑releasing hormone (like sermorelin). It also appears to block the usual feedback that stops GH release, likely by lowering somatostatin. For biohackers, this hints that pairing a mild cholinergic enhancer with a GHRH peptide could give a bigger GH boost, but the research is tiny and short‑term, so safety and dosing need careful consideration.

Utility 4
pubmed May 1, 1988

Continuous subcutaneous growth hormone releasing factor analogue augments growth hormone secretion in normal male subjects with no desensitization of the somatotroph.

Brain. C C; Hindmarsh. P C PC; Brook. C G CG; Matthews. D R DR

A study gave healthy men a continuous skin‑pump infusion of the growth‑hormone‑releasing peptide sermorelin for eight days and found that doses above 30 ng/kg/min boosted both the size and number of GH spikes, with 60‑120 ng/kg/min being the most effective. Even the highest dose didn’t cause the body to stop responding, and GH stayed elevated for long periods, suggesting you can safely use higher, steady doses without the hormone system getting tired.

Utility 4
pubmed Dec 1, 1986

The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships.

Vance. M L ML; Evans. W S WS; Kaiser. D L DL; Burke. R L RL; Rivier. J J; Vale. W W; Thorner. M O MO

The study shows that the GH‑releasing peptide [Nle27]GHRH(1‑29)NH2 (similar to sermorelin) can boost growth hormone when given IV, under the skin, or as a nasal spray. Injecting under the skin works well but needs about ten times the dose used for IV, while the nasal spray needs about thirty times the IV dose and only gives about one‑fifth the hormone boost. The hormone rise starts within 5‑10 minutes, peaks around 30 minutes, and returns to normal after about two hours, with no side effects reported.

Utility 4
pubmed Jun 22, 1987

Effect of long-term administration of an analog of growth hormone-releasing factor on the GH response in rats.

Karashima. T T; Olsen. D D; Schally. A V AV

In rats, a single injection of the sermorelin‑like peptide caused a big, lasting boost in growth hormone, but giving the same dose twice a day for weeks made the pituitary less responsive. A slow, continuous low‑dose infusion didn’t cause this drop, suggesting the way you dose matters for keeping the effect alive.

Utility 4
pubmed Mar 14, 1995

Growth hormone-releasing hormone stimulates cAMP release in superfused rat pituitary cells.

Horváth. J E JE; Groot. K K; Schally. A V AV

In rat pituitary cells, giving short bursts of growth‑hormone‑releasing hormone (GHRH) triggers both growth hormone (GH) and the messenger molecule cAMP, but the two don't rise together. Low GHRH doses barely raise cAMP, and even high doses make cAMP keep climbing while GH plateaus. Repeating GHRH pulses makes the cells lose their GH response faster than their cAMP response, and somatostatin can shut down GH release without stopping the immediate cAMP spike.

Utility 4
pubmed 2005

Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects.

Munafo. A A; Nguyen. T X Q TX; Papasouliotis. O O; Lécuelle. H H; Priestley. A A; Thorner. M O...

A modified version of growth‑hormone‑releasing hormone (PEG‑GHRH) stays in the body longer, causing a clear rise in growth hormone for up to 12 hours after one shot and even longer with repeated doses, especially in older people. It also raises IGF‑1 levels. Side effects are mild injection‑site irritation, but repeated dosing in older adults can slightly worsen glucose tolerance. No immune reactions were seen.

Utility 4
pubmed 1997

Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.

Khorram. O O; Laughlin. G A GA; Yen. S S SS

In a small study of people aged 55‑71, giving a nightly injection of a growth‑hormone‑releasing hormone (GHRH) analog (10 µg per kg) for four months boosted nighttime GH and IGF‑1 levels. Men saw modest gains in lean muscle, better insulin sensitivity, and felt better overall, while both men and women had thicker skin. Blood pressure and weight stayed the same, and the only side effect was a short‑lived rise in blood fats.

Utility 4
pubmed 2001

The growth hormone-releasing hormone receptor: desensitisation following short-term agonist exposure.

Hansen. B S BS; Gerlach. L O LO; Hansen. A A; Foged. C C; Andersen. P H PH

The study shows that giving growth hormone‑releasing hormone (GHRH) or its analogs like sermorelin repeatedly over a short period makes the receptors on pituitary cells less responsive. This desensitisation reduces the amount of growth hormone released, especially when the hormone is given too often or at high doses. The effect is seen both in human‑derived cells and in rat pituitary cells, meaning it likely applies to humans too.

Utility 4
pubmed Dec 3, 1984

Stimulation of growth hormone secretion with human growth hormone releasing factors (GRF1-44, GRF1-40, GRF1-29) in normal subjects.

Losa. M M; Schopohl. J J; Müller. O A OA; von Werder. K K

Giving a single 50 µg dose of the short growth‑hormone‑releasing peptide (GRF1‑29, also known as sermorelin) causes a clear spike in growth hormone within 15‑30 minutes, and this effect repeats safely when the dose is given every 6 hours.

Utility 4
pubmed 1986

Growth hormone releasing hormone.

Grossman. A A; Savage. M O MO; Besser. G M GM

GHRH (the natural hormone that tells the pituitary to release growth hormone) and its synthetic versions like sermorelin can safely boost GH levels when given in short, pulsed doses. The effect drops off if you give it continuously, and factors like excess body fat, high blood sugar, or free fatty acids can blunt the response. In kids with GH deficiency it can even speed growth, but in healthy adults it’s mainly a way to raise GH modestly.

Utility 3
pubmed Nov 1, 1999

The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals.

Achermann. J C JC; Hindmarsh. P C PC; Robinson. I C IC; Matthews. D R DR; Brook. C G CG

The study shows that giving a steady infusion of a GHRH peptide (like sermorelin) raises the height of growth hormone spikes in healthy people, and that pairing it with short breaks in somatostatin (the hormone that blocks GH) can make those spikes more regular. However, in people who had high‑dose brain radiation, the GH response was much weaker, suggesting damage to the pituitary limits how much GHRH can help.

Utility 3
pubmed Oct 12, 2015

Operation resistance: A snapshot of falsified antibiotics and biopharmaceutical injectables in Europe.

Venhuis. Bastiaan J BJ; Keizers. Peter H J PH; Klausmann. Rüdiger R; Hegger. Ingrid I

The study looked at fake antibiotics and injectable drugs like sermorelin that were seized across Europe during a big anti‑counterfeit operation. It found that while most of the seized items were antibiotics, a few bogus injectable products—including human growth hormone, sermorelin, and melanotan II—were also found, often in large shipments meant for resale rather than personal use.

Utility 3
pubmed Jan 1, 1998

Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary restriction in patients with Cushing's syndrome.

Leal-Cerro. A A; Venegas. E E; Garcia-Pesquera. F F; Jimenez. L M LM; Astorga. R R; Casanueva. F F F...

A tiny study found that women with Cushing's disease, who normally have weak growth‑hormone (GH) spikes when given a GH‑releasing hormone (like sermorelin), showed a big jump in GH after just three days of a very low‑calorie diet (650 kcal/day). This suggests that short‑term calorie restriction can make the body more responsive to GH‑releasing signals, even when cortisol is high.

Utility 3
pubmed Aug 1, 2004

Potent trypsin-resistant hGH-RH analogues.

Izdebski. Jan J; Witkowska. Ewa E; Kunce. Danuta D; Orłowska. Alicja A; Baranowska. Bogus&#x14...

Researchers made new versions of the growth‑hormone‑releasing hormone (GHRH) that are much harder for the body to break down and work about 50 times better than the original peptide in rats. These modified peptides could eventually be used to treat growth‑hormone deficiency, but they have only been tested in animals so far.

Utility 3
pubmed Jul 19, 2013

Growth hormone releasing hormone (GHRH) signaling modulates intermittent hypoxia-induced oxidative stress and cognitive deficits in mouse.

Nair. Deepti D; Ramesh. Vijay V; Li. Richard C RC; Schally. Andrew V AV; Gozal. David D

In mice that were exposed to the kind of oxygen drops that happen in sleep apnea, a drug that mimics the natural hormone that tells the body to release growth hormone (a GHRH agonist similar to sermorelin) helped protect the brain. It lowered markers of oxidative damage, boosted protective factors like IGF‑1 and erythropoietin, and improved performance on memory tests. The opposite—blocking GHRH—did not help.

Utility 3
pubmed Oct 1, 2006

Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.

Grugni. G G; Marzullo. P P; Ragusa. L L; Sartorio. A A; Trifirò. G G; Liuzzi. A A; Crinò....

In adults with Prader‑Willi syndrome, the pituitary gland doesn’t respond well to a combined GH‑releasing hormone (GHRH) and arginine test, showing lower growth hormone spikes and lower IGF‑I levels than obese controls. About 39% of the PWS participants met criteria for severe growth‑hormone deficiency, and this deficiency wasn’t just because they were overweight.

Utility 3
pubmed 1996

Characterization of the hypothalamo-pituitary-IGF-I axis in rats made obese by overfeeding.

Cattaneo. L L; De Gennaro Colonna. V V; Zoli. M M; Müller. E E; Cocchi. D D

In rats that became obese by eating a high‑calorie diet, their bodies released less growth hormone (GH) when given a burst of GHRH, even though the pituitary gland still had normal GH stores and IGF‑I levels were unchanged. This reduced GH response seems to come from factors outside the brain, not from a lack of GHRH signals, and it goes away when the animals lose weight.

Utility 3
pubmed 2015

New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor.

Kanashiro-Takeuchi. Rosemeire M RM; Szalontay. Luca L; Schally. Andrew V AV; Takeuchi. Lauro M LM; P...

In rats with heart attacks, new drugs that mimic the hormone that tells the body to release growth hormone (like sermorelin) helped the heart heal faster. They cut down the size of the damage, lowered inflammation, and boosted the growth of repair cells and blood vessels.

Utility 3
pubmed 1994

Low-dose growth hormone-releasing hormone tests: a dose-response study.

Spoudeas. H A HA; Winrow. A P AP; Hindmarsh. P C PC; Brook. C G CG

In a small study of 10 healthy men, giving the GHRH peptide (sermorelin) by IV injection showed that a 10‑µg dose already caused a clear growth‑hormone spike, while a 1‑µg dose did not. A 100‑µg dose produced a similar peak but kept hormone levels higher for a longer time, with the peak arriving later and GH staying elevated for up to two hours.